➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Mallinckrodt
Express Scripts
Merck
McKinsey
Dow

Last Updated: September 27, 2021

DrugPatentWatch Database Preview

Details for Patent: 6,562,873


Email this page to a colleague

« Back to Dashboard

Which drugs does patent 6,562,873 protect, and when does it expire?

Patent 6,562,873 protects ALPHAGAN P and is included in two NDAs.

Protection for ALPHAGAN P has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has twenty-seven patent family members in twenty-two countries.

Summary for Patent: 6,562,873
Title: Compositions containing therapeutically active components having enhanced solubility
Abstract:Compositions which include therapeutically active components, solubility enhancing components other than cyclodextrins, and oxy-chloro components, wherein the oxy-chloro components are substantially effective as preservatives. In one embodiment, the oxy-chloro components are useful for preserving the therapeutically active components. In one embodiment, the oxy-chloro components include chlorite components. In a useful embodiment, the solubility enhancing components include carboxymethylcellulose.
Inventor(s): Olejnik; Orest (Coto de Coza, CA), Kerslake; Edward D. S. (Charleston, MA)
Assignee: Allergan, Inc. (Irvine, CA)
Application Number:09/903,962
Patent Claim Types:
see list of patent claims
Composition; Formulation;

Drugs Protected by US Patent 6,562,873

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Allergan ALPHAGAN P brimonidine tartrate SOLUTION/DROPS;OPHTHALMIC 021770-001 Aug 19, 2005 RX Yes Yes ⤷  Try it Free ⤷  Try it Free Y ⤷  Try it Free
Allergan ALPHAGAN P brimonidine tartrate SOLUTION/DROPS;OPHTHALMIC 021262-001 Mar 16, 2001 AT RX Yes Yes ⤷  Try it Free ⤷  Try it Free Y ⤷  Try it Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 6,562,873

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 035039 ⤷  Try it Free
Australia 2001273268 ⤷  Try it Free
Australia 2005234735 ⤷  Try it Free
Australia 7326801 ⤷  Try it Free
Brazil 0112461 ⤷  Try it Free
Canada 2416169 ⤷  Try it Free
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Merck
AstraZeneca
McKinsey
Harvard Business School
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.